|
Ahmed, I., E. Adeghate, E. Cummings, A. K. Sharma, and J. Singh. 2004. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 261:63-70. del Aguila, L. F., K. P. Claffey, and J. P. Kirwan. 1999. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 276:E849-55. Baron, V., P. Kaliman, N. Gautier, and E. Van Obberghen. 1992. The insulin receptor activation process involves localized conformational changes. J Biol Chem 267:23290-4. Bhattacharya, S., D. Dey, and S. S. Roy. 2007. Molecular mechanism of insulin resistance. J Biosci 32:405-13. Boden, G., and L. H. Carnell. 2003. Nutritional effects of fat on carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab 17:399-410. Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-8. Bouzakri, K., and J. R. Zierath. 2007. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 282:7783-9. Carter, S. K., L. Broder, and M. Friedman. 1971. Streptozotocin and metastatic insulinoma. Ann Intern Med 74:445-6. Carvalho-Filho, M. A., M. Ueno, J. B. Carvalheira, L. A. Velloso, and M. J. Saad. 2006. Targeted disruption of iNOS prevents LPS-induced S-nitrosation of IRbeta/IRS-1 and Akt and insulin resistance in muscle of mice. Am J Physiol Endocrinol Metab 291:E476-82. Carvalho-Filho, M. A., M. Ueno, S. M. Hirabara, A. B. Seabra, J. B. Carvalheira, M. G. de Oliveira, L. A. Velloso, R. Curi, and M. J. Saad. 2005. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 54:959-67. Chan, A. Y., and J. R. Dyck. 2005. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 83:24-8. Chao-Pin, L., Y. Guy, and O. Seung Joon. 2002. Type 2 diabetes--delivery approaches for novel therapeutics. Adv Drug Deliv Rev 54:1161-3. Cheatham, B., and C. R. Kahn. 1995. Insulin action and the insulin signaling network. Endocr Rev 16:117-42. Chen, H. 2006. Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol Res 53:469-77. Cheng, H. L., H. K. Huang, C. I. Chang, C. P. Tsai, and C. H , Chou. 2008. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem. in press. Choi, S. E., H. L. Noh, H. M. Kim, J. W. Yoon, and Y. Kang. 2002. Streptozotocin upregulates GAD67 expression in MIN6N8a mouse beta cells. J Autoimmun 19:1-8. Conrad, B., E. Weidmann, G. Trucco, W. A. Rudert, R. Behboo, C. Ricordi, H. Rodriquez-Rilo, D. Finegold, and M. Trucco. 1994. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371:351-5. Dandona, P., A. Aljada, and A. Bandyopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7. DeFronzo, R. A. 1988. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-87. Dresner, A., D. Laurent, M. Marcucci, M. E. Griffin, S. Dufour, G. W. Cline, L. A. Slezak, D. K. Andersen, R. S. Hundal, D. L. Rothman, K. F. Petersen, and G. I. Shulman. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-9. Dunne, F. 2005. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med 10:333-9. Eisenbarth, G. S. 1986. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360-8. Fisher, J. S., J. Gao, D. H. Han, J. O. Holloszy, and L. A. Nolte. 2002. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 282:E18-23. Fujii, N., N. Jessen, and L. J. Goodyear. 2006. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 291:E867-77. Fujimoto, M., N. Shimizu, K. Kunii, J. A. Martyn, K. Ueki, and M. Kaneki. 2005. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54:1340-8. Gao, Z., D. Hwang, F. Bataille, M. Lefevre, D. York, M. J. Quon, and J. Ye. 2002. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 277:48115-21. Garcia-Puig, J., L. M. Ruilope, M. Luque, J. Fernandez, R. Ortega, and R. Dal-Re. 2006. Glucose metabolism in patients with essential hypertension. Am J Med 119:318-26. Gerich, J. E. 2003. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78:447-56. Goldstein, B. J. 2002. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90:3-10. Graham, D. J., L. Green, J. R. Senior, and P. Nourjah. 2003. Troglitazone-induced liver failure: a case study. Am J Med 114:299-306. Greenfield, J. R., and L. V. Campbell. 2004. Insulin resistance and obesity. Clin Dermatol 22:289-95. Gual, P., Y. Le Marchand-Brustel, and J. F. Tanti. 2005. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99-109. Hanada, T., and A. Yoshimura. 2002. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13:413-21. Hanley, A. J., K. Williams, M. P. Stern, and S. M. Haffner. 2002. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25:1177-84. Hardie, D. G. 2004. The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci 117:5479-87. Harinantenaina, L., M. Tanaka, S. Takaoka, M. Oda, O. Mogami, M. Uchida, and Y. Asakawa. 2006. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo) 54:1017-21. Herrera, R., and O. M. Rosen. 1986. Autophosphorylation of the insulin receptor in vitro. Designation of phosphorylation sites and correlation with receptor kinase activation. J Biol Chem 261:11980-5. Hevener, A. L., D. Reichart, A. Janez, and J. Olefsky. 2001. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. Diabetes 50:2316-22. Hou, J. C., and J. E. Pessin. 2007. Ins (endocytosis) and outs (exocytosis) of GLUT4 trafficking. Curr Opin Cell Biol 19:466-73. Huang, S., and M. P. Czech. 2007. The GLUT4 glucose transporter. Cell Metab 5:237-52. Isomaa, B., P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M. R. Taskinen, and L. Groop. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-9. Iwata, M., T. Haruta, I. Usui, Y. Takata, A. Takano, T. Uno, J. Kawahara, E. Ueno, T. Sasaoka, and M. Ishibayashi. 2001. Pioglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferators-activated receptor-γ. Diabetes 50: 1083-1092. Janjic, D., P. Maechler, N. Sekine, C. Bartley, A. S. Annen, and C. B. Wolheim. 1999. Free radical modulation of insulin release in INS-1 cells exposed to alloxan. Biochem Pharmacol 57:639-48. Junod, A., A. E. Lambert, W. Stauffacher, and A. E. Renold. 1969. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 48:2129-39. Kahn, B. B., T. Alquier, D. Carling, and D. G. Hardie. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25. Kahn, B. B., and J. S. Flier. 2000. Obesity and insulin resistance. J Clin Invest 106:473-81. Kanzaki, M., and J. E. Pessin. 2001. Signal integration and the specificity of insulin action. Cell Biochem Biophys 35:191-209. Khanna, P., S. C. Jain, A. Panagariya, and V. P. Dixit. 1981. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44:648-55. Kumar, N., and C. S. Dey. 2003. Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochem Pharmacol 65:249-57. Langer, O., Y. Yogev, O. Most, and E. M. Xenakis. 2005. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 192:989-97. Lebovitz, H. E. 2001. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 109 Suppl 2:S135-48. Lebovitz, H. E. 2001. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 30:909-33. Lebovitz, H. E. 2002. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 90:34-41. Lebovitz, H. E., and M. A. Banerji. 2004. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol 490:135-46. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-6. Lillioja, S., D. M. Mott, B. V. Howard, P. H. Bennett, H. Yki-Jarvinen, D. Freymond, B. L. Nyomba, F. Zurlo, B. Swinburn, and C. Bogardus. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-25. Lindsley, J. E., and J. Rutter. 2004. Nutrient sensing and metabolic decisions. Comp Biochem Physiol B Biochem Mol Biol 139:543-59. Long, Y. C., and J. R. Zierath. 2006. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776-83. de Luca, C., and J. M. Olefsky. 2008. Inflammation and insulin resistance. FEBS Lett 582:97-105. Maresh, M. 2001. Diabetes in pregnancy. Curr Opin Obstet Gynecol 13:103-7. McCarty, M. F. 2004. Does bitter melon contain an activator of AMP-activated kinase? Med Hypotheses 63:340-3. McEvoy, G. K. 2005. Dose adjustment in renal impairment: response from AHFS Drug Information. Bmj 331:293. Mlinar, B., J. Marc, A. Janez, and M. Pfeifer. 2007. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 375:20-35. Moule, S. K., and R. M. Denton. 1997. Multiple signaling pathways involved in the metabolic effects of insulin. Am J Cardiol 80:41A-49A. Munoz, P., J. Chillaron, M. Camps, A. Castello, M. Furriols, X. Testar, M. Palacin, and A. Zorzano. 1996. Evidence for posttranscriptional regulation of GLUT4 expression in muscle and adipose tissue from streptozotocin-induced diabetic and benfluorex-treated rats. Biochem Pharmacol 52:1665-73. Perreault, M., and A. Marette. 2001. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138-43. Pessin, J. E., and A. R. Saltiel. 2000. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165-9. Pietropaolo, M. and D. L. Roith. 2002. Pathogenesis of diabetes: our current understanding. Diabetes 4: 1-16. Proietto, J., and S. Andrikopoulos. 2004. Molecular mechanisms of increased glucose production: identifying potential therapeutic targets. J Investig Med 52:389-93. Rakieten, N., M. L. Rakieten, and M. V. Nadkarni. 1963. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep 29:91-8. Rangwala, S. M., and M. A. Lazar. 2004. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-6. Reaven, G. M. 1993. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44:121-31. Rendell, M. S., and L. Jovanovic. 2006. Targeting postprandial hyperglycemia. Metabolism 55:1263-81. Roffey, B. W., A. S. Atwal, T. Johns, and S. Kubow. 2007. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 112:77-84. Ruland, J., and T. W. Mak. 2003. From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-kappaB. Semin Immunol 15:177-83. Saha, A. K., P. R. Avilucea, J. M. Ye, M. M. Assifi, E. W. Kraegen, and N. B. Ruderman. 2004. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314:580-5. Sandler, S., and A. Andersson. 1985. Modulation of streptozotocin-induced insulitis and hyperglycaemia in the mouse. Acta Pathol Microbiol Immunol Scand [A] 93:93-8. Sarkar, S., M. Pranava, and R. Marita. 1996. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 33:1-4. Sato, Y., N. Hotta, N. Sakamoto, S. Matsuoka, N. Ohishi, and K. Yagi. 1979. Lipid peroxide level in plasma of diabetic patients. Biochem Med 21:104-7. Scollan-Koliopoulos, M., S. Guadagno, and E. A. Walker. 2006. Gestational diabetes management: guidelines to a healthy pregnancy. Nurse Pract 31:14-23; quiz 24-5. Shepherd, P. R., and B. B. Kahn. 1999. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-57. Shoelson, S. E., L. Herrero, and A. Naaz. 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169-80. Shulman, G. I. 2000. Cellular mechanisms of insulin resistance. J Clin Invest 106:171-6. Shulman, G. I., D. L. Rothman, T. Jue, P. Stein, R. A. DeFronzo, and R. G. Shulman. 1990. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322:223-8. Sitasawad, S. L., Y. Shewade, and R. Bhonde. 2000. Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J Ethnopharmacol 73:71-9. Stein, M. P., J. Dong, and A. Wandinger-Ness. 2003. Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv Drug Deliv Rev 55:1421-37. Stenmark, H., and V. M. Olkkonen. 2001. The Rab GTPase family. Genome Biol 2:reviews3007.1-3007.7 Strubbe, J. H., and A. B. Steffens. 1988. Hormonal modifications induced by food intake contribute to the regulation of the body weight and to metabolic variations. Ann Endocrinol (Paris) 49:105-12. Tan, M. J., J. M. Ye, N. Turner, C. Hohnen-Behrens, C. Q. Ke, C. P. Tang, T. Chen, H. C. Weiss, E. R. Gesing, A. Rowland, D. E. James, and Y. Ye. 2008. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15:263-73. Thong, F. S., P. J. Bilan, and A. Klip. 2007. The Rab GTPase-activating protein AS160 integrates Akt, protein kinase C, and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 56:414-23. Tilg, H., and G. S. Hotamisligil. 2006. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131:934-45. Treebak, J. T., S. Glund, A. Deshmukh, D. K. Klein, Y. C. Long, T. E. Jensen, S. B. Jorgensen, B. Viollet, L. Andersson, D. Neumann, T. Wallimann, E. A. Richter, A. V. Chibalin, J. R. Zierath, and J. F. Wojtaszewski. 2006. AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes 55:2051-8. Truglia, J. A., G. R. Hayes, and D. H. Lockwood. 1988. Intact adipocyte insulin-receptor phosphorylation and in vitro tyrosine kinase activity in animal models of insulin resistance. Diabetes 37:147-53. van Haeften, T. W. 2002. Early disturbances in insulin secretion in the development of type 2 diabetes mellitus. Mol Cell Endocrinol 197:197-204. Viollet, B., M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, and F. Andreelli. 2006. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574:41-53. Viollet, B., R. Mounier, J. Leclerc, A. Yazigi, M. Foretz, and F. Andreelli. 2007. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33:395-402. Virdi, J., S. Sivakami, S. Shahani, A. C. Suthar, M. M. Banavalikar, and M. K. Biyani. 2003. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88:107-11. Wang, H. J., Y. X. Jin, W. Shen, J. Neng, T. Wu, Y. J. Li, and Z. W. Fu. 2007. Low dose streptozotocin (STZ) combined with high energy intake can effectively induce type 2 diabetes through altering the related gene expression. Asia Pac J Clin Nutr 16 Suppl 1:412-7. Watson, R. T., M. Kanzaki, and J. E. Pessin. 2004. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev 25:177-204. Watson, R. T., and J. E. Pessin. 2006. Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem Sci 31:215-22. Watson, R. T., and J. E. Pessin. 2007. GLUT4 translocation: the last 200 nanometers. Cell Signal 19:2209-17. Weyer, C., C. Bogardus, D. M. Mott, and R. E. Pratley. 1999. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-94. White, F. R. 1963. Streptozotocin. Cancer Chemother Rep 30:49-53. Wilson, G. L., P. C. Hartig, N. J. Patton, and S. P. LeDoux. 1988. Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution. Diabetes 37:213-6. Wood, I. S., L. Hunter, and P. Trayhurn. 2003. Expression of Class III facilitative glucose transporter genes (GLUT-10 and GLUT-12) in mouse and human adipose tissues. Biochem Biophys Res Commun 308:43-9. Worley, J. F., 3rd, M. S. McIntyre, B. Spencer, and I. D. Dukes. 1994. Depletion of intracellular Ca2+ stores activates a maitotoxin-sensitive nonselective cationic current in beta-cells. J Biol Chem 269:32055-8. Wu, X., W. Li, V. Sharma, A. Godzik, and H. H. Freeze. 2002. Cloning and characterization of glucose transporter 11, a novel sugar transporter that is alternatively spliced in various tissues. Mol Genet Metab 76:37-45. Wullaert, A., K. Heyninck, and R. Beyaert. 2006. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 72:1090-101. Yasukawa, T., E. Tokunaga, H. Ota, H. Sugita, J. A. Martyn, and M. Kaneki. 2005. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 280:7511-8. Zick, Y. 2001. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 11:437-41.
|